CRSP
Price
$52.17
Change
+$0.50 (+0.97%)
Updated
Jul 3 closing price
Capitalization
4.51B
37 days until earnings call
MNMD
Price
$7.17
Change
+$0.09 (+1.27%)
Updated
Jul 3 closing price
Capitalization
541.72M
40 days until earnings call
Interact to see
Advertisement

CRSP vs MNMD

Header iconCRSP vs MNMD Comparison
Open Charts CRSP vs MNMDBanner chart's image
CRISPR Therapeutics AG
Price$52.17
Change+$0.50 (+0.97%)
Volume$1.84M
Capitalization4.51B
Mind Medicine (MindMed)
Price$7.17
Change+$0.09 (+1.27%)
Volume$583.98K
Capitalization541.72M
CRSP vs MNMD Comparison Chart in %
Loading...
CRSP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MNMD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CRSP vs. MNMD commentary
Jul 05, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CRSP is a StrongBuy and MNMD is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 05, 2025
Stock price -- (CRSP: $52.17 vs. MNMD: $7.17)
Brand notoriety: CRSP and MNMD are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CRSP: 68% vs. MNMD: 50%
Market capitalization -- CRSP: $4.51B vs. MNMD: $541.72M
CRSP [@Biotechnology] is valued at $4.51B. MNMD’s [@Biotechnology] market capitalization is $541.72M. The market cap for tickers in the [@Biotechnology] industry ranges from $310.37B to $0. The average market capitalization across the [@Biotechnology] industry is $2.38B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CRSP’s FA Score shows that 0 FA rating(s) are green whileMNMD’s FA Score has 1 green FA rating(s).

  • CRSP’s FA Score: 0 green, 5 red.
  • MNMD’s FA Score: 1 green, 4 red.
According to our system of comparison, MNMD is a better buy in the long-term than CRSP.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CRSP’s TA Score shows that 5 TA indicator(s) are bullish while MNMD’s TA Score has 6 bullish TA indicator(s).

  • CRSP’s TA Score: 5 bullish, 4 bearish.
  • MNMD’s TA Score: 6 bullish, 5 bearish.
According to our system of comparison, both CRSP and MNMD are a good buy in the short-term.

Price Growth

CRSP (@Biotechnology) experienced а +11.71% price change this week, while MNMD (@Biotechnology) price change was +6.38% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +6.93%. For the same industry, the average monthly price growth was +17.38%, and the average quarterly price growth was -0.11%.

Reported Earning Dates

CRSP is expected to report earnings on Aug 11, 2025.

MNMD is expected to report earnings on Aug 14, 2025.

Industries' Descriptions

@Biotechnology (+6.93% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CRSP($4.51B) has a higher market cap than MNMD($542M). CRSP YTD gains are higher at: 32.546 vs. MNMD (3.017). MNMD has higher annual earnings (EBITDA): -75.18M vs. CRSP (-455.24M). CRSP has more cash in the bank: 1.86B vs. MNMD (212M). MNMD has less debt than CRSP: MNMD (22M) vs CRSP (219M). CRSP has higher revenues than MNMD: CRSP (35M) vs MNMD (0).
CRSPMNMDCRSP / MNMD
Capitalization4.51B542M831%
EBITDA-455.24M-75.18M606%
Gain YTD32.5463.0171,079%
P/E RatioN/AN/A-
Revenue35M0-
Total Cash1.86B212M875%
Total Debt219M22M995%
FUNDAMENTALS RATINGS
CRSP vs MNMD: Fundamental Ratings
CRSP
MNMD
OUTLOOK RATING
1..100
4762
VALUATION
overvalued / fair valued / undervalued
1..100
67
Overvalued
31
Undervalued
PROFIT vs RISK RATING
1..100
10095
SMR RATING
1..100
9496
PRICE GROWTH RATING
1..100
3853
P/E GROWTH RATING
1..100
81100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

MNMD's Valuation (31) in the null industry is somewhat better than the same rating for CRSP (67) in the Biotechnology industry. This means that MNMD’s stock grew somewhat faster than CRSP’s over the last 12 months.

MNMD's Profit vs Risk Rating (95) in the null industry is in the same range as CRSP (100) in the Biotechnology industry. This means that MNMD’s stock grew similarly to CRSP’s over the last 12 months.

CRSP's SMR Rating (94) in the Biotechnology industry is in the same range as MNMD (96) in the null industry. This means that CRSP’s stock grew similarly to MNMD’s over the last 12 months.

CRSP's Price Growth Rating (38) in the Biotechnology industry is in the same range as MNMD (53) in the null industry. This means that CRSP’s stock grew similarly to MNMD’s over the last 12 months.

CRSP's P/E Growth Rating (81) in the Biotechnology industry is in the same range as MNMD (100) in the null industry. This means that CRSP’s stock grew similarly to MNMD’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CRSPMNMD
RSI
ODDS (%)
Bearish Trend 3 days ago
80%
Bearish Trend 3 days ago
90%
Stochastic
ODDS (%)
Bearish Trend 3 days ago
85%
Bullish Trend 3 days ago
86%
Momentum
ODDS (%)
Bullish Trend 3 days ago
82%
Bullish Trend 3 days ago
83%
MACD
ODDS (%)
Bullish Trend 3 days ago
61%
Bearish Trend 3 days ago
87%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
76%
Bullish Trend 3 days ago
86%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
77%
Bearish Trend 3 days ago
87%
Advances
ODDS (%)
Bullish Trend 3 days ago
78%
Bullish Trend 3 days ago
84%
Declines
ODDS (%)
Bearish Trend 24 days ago
84%
Bearish Trend 6 days ago
86%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
90%
Bullish Trend 3 days ago
82%
Aroon
ODDS (%)
Bullish Trend 3 days ago
74%
Bearish Trend 3 days ago
89%
View a ticker or compare two or three
Interact to see
Advertisement
CRSP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MNMD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
BUIMX17.420.16
+0.93%
Buffalo Mid Cap Growth Inst
MGPIX107.760.83
+0.78%
ProFunds Mid Cap Growth Inv
MRGSX23.040.13
+0.57%
BlackRock Advantage Global R
BOSOX17.880.10
+0.56%
Boston Trust Walden Small Cap
JSEAX21.80-0.05
-0.23%
JPMorgan International Equity A

CRSP and

Correlation & Price change

A.I.dvisor indicates that over the last year, CRSP has been closely correlated with RXRX. These tickers have moved in lockstep 72% of the time. This A.I.-generated data suggests there is a high statistical probability that if CRSP jumps, then RXRX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CRSP
1D Price
Change %
CRSP100%
+0.97%
RXRX - CRSP
72%
Closely correlated
+1.15%
BEAM - CRSP
72%
Closely correlated
+0.65%
NTLA - CRSP
66%
Loosely correlated
+0.09%
PRME - CRSP
64%
Loosely correlated
+1.30%
CRBU - CRSP
63%
Loosely correlated
N/A
More

MNMD and

Correlation & Price change

A.I.dvisor indicates that over the last year, MNMD has been loosely correlated with ATAI. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if MNMD jumps, then ATAI could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MNMD
1D Price
Change %
MNMD100%
+1.27%
ATAI - MNMD
53%
Loosely correlated
+0.73%
BEAM - MNMD
51%
Loosely correlated
+0.65%
EYPT - MNMD
50%
Loosely correlated
N/A
RXRX - MNMD
49%
Loosely correlated
+1.15%
CRSP - MNMD
49%
Loosely correlated
+0.97%
More